Skip to content

Research at St Andrews

XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High?

Research output: Contribution to journalReview article

Standard

XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High? / Gillespie, Stephen Henry; Singh, Kasha.

In: Recent Patents Anti-infective Drug Discovery, Vol. 6, No. 2, 31.05.2011, p. 77.

Research output: Contribution to journalReview article

Harvard

Gillespie, SH & Singh, K 2011, 'XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High?', Recent Patents Anti-infective Drug Discovery, vol. 6, no. 2, pp. 77.

APA

Gillespie, S. H., & Singh, K. (2011). XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High? Recent Patents Anti-infective Drug Discovery, 6(2), 77.

Vancouver

Gillespie SH, Singh K. XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High? Recent Patents Anti-infective Drug Discovery. 2011 May 31;6(2):77.

Author

Gillespie, Stephen Henry ; Singh, Kasha. / XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High?. In: Recent Patents Anti-infective Drug Discovery. 2011 ; Vol. 6, No. 2. pp. 77.

Bibtex - Download

@article{6e2aef367fac45099d93583ca275a803,
title = "XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High?",
abstract = "Drug resistance is a major hurdle in the global battle against tuberculosis (TB). In tackling this problem it is important to understand both how resistance emerges as well as the ways in which multi-drug and extensively drug-resistant TB (M/XDR-TB) may be successfully treated. The biggest problem with treatment is the lack of effective drugs. Exciting developments have been made in this area over recent years with useful drugs being found from older agents as well as new discoveries. Patent applications are being made for novel agents and are also possible as new use for older agents such as thioridazine. A flourishing drug pipeline is critical if we are to make progress in the management of M/XDR-TB.",
keywords = "tuberculosis, MDR, XDR, New Therapy, Drug Discovery",
author = "Gillespie, {Stephen Henry} and Kasha Singh",
year = "2011",
month = "5",
day = "31",
language = "English",
volume = "6",
pages = "77",
journal = "Recent Patents Anti-infective Drug Discovery",
number = "2",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - XDR-TB, What is it; How is it Treated; and Why is Therapeutic Failure so High?

AU - Gillespie, Stephen Henry

AU - Singh, Kasha

PY - 2011/5/31

Y1 - 2011/5/31

N2 - Drug resistance is a major hurdle in the global battle against tuberculosis (TB). In tackling this problem it is important to understand both how resistance emerges as well as the ways in which multi-drug and extensively drug-resistant TB (M/XDR-TB) may be successfully treated. The biggest problem with treatment is the lack of effective drugs. Exciting developments have been made in this area over recent years with useful drugs being found from older agents as well as new discoveries. Patent applications are being made for novel agents and are also possible as new use for older agents such as thioridazine. A flourishing drug pipeline is critical if we are to make progress in the management of M/XDR-TB.

AB - Drug resistance is a major hurdle in the global battle against tuberculosis (TB). In tackling this problem it is important to understand both how resistance emerges as well as the ways in which multi-drug and extensively drug-resistant TB (M/XDR-TB) may be successfully treated. The biggest problem with treatment is the lack of effective drugs. Exciting developments have been made in this area over recent years with useful drugs being found from older agents as well as new discoveries. Patent applications are being made for novel agents and are also possible as new use for older agents such as thioridazine. A flourishing drug pipeline is critical if we are to make progress in the management of M/XDR-TB.

KW - tuberculosis

KW - MDR

KW - XDR

KW - New Therapy

KW - Drug Discovery

M3 - Review article

VL - 6

SP - 77

JO - Recent Patents Anti-infective Drug Discovery

JF - Recent Patents Anti-infective Drug Discovery

IS - 2

ER -

Related by author

  1. Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection

    Kloprogge, F., Hammond, R., Kipper, K., Gillespie, S. H. & Della Pasqua, O., 13 Sep 2019, In : Scientific Reports. 9, 8 p., 13228.

    Research output: Contribution to journalArticle

  2. A tuberculosis molecular bacterial load assay (TB-MBLA)

    Sabiiti, W., Mtafya, B. A., Alferes De Lima, D., Dombay, E., Baron, V. O., Azam, K., Orascova, K., Sloan, D. J. & Gillespie, S. H., 6 Sep 2019, (Accepted/In press) In : Journal of Visualized Experiments.

    Research output: Contribution to journalArticle

  3. Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?

    Kloprogge, F., Hammond, R., Copas, A., Gillespie, S. H. & Della Pasqua, O., 25 Aug 2019, In : Journal of Antimicrobial Chemotherapy. Advance article, 7 p.

    Research output: Contribution to journalArticle

  4. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

    Tweed, C. D., Crook, A. M., Dawson, R., Diacon, A. H., McHugh, T. D., Mendel, C. M., Meredith, S. K., Mohapi, L., Murphy, M. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M. & Gillespie, S. H., 14 Aug 2019, In : BMC Pulmonary Medicine. 19, 9 p., 152.

    Research output: Contribution to journalArticle

  5. Model-based relationship between the molecular bacterial load assay and time-to-positivity in liquid culture

    Svensson, R. J., Sabiiti, W., Kibiki, G. S., Ntinginya, N. E., Bhatt, N., Davies, G., Gillespie, S. H. & Simonsson, U. S. H., 29 Jul 2019, In : Antimicrobial Agents and Chemotherapy. Early

    Research output: Contribution to journalArticle

ID: 10380451

Top